TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
Rhea-AI Summary
TG Therapeutics (NASDAQ: TGTX) secured a new five-year $750 million senior secured credit facility with funds managed by Blue Owl, repaid its prior $250 million facility and thus raised 500 million of net non-dilutive capital. The facility can be increased by $250 million to a total of $1 billion at mutual discretion.
The Board expanded the share repurchase program from $100 million to $300 million; as of March 18, 2026 the company repurchased about $38 million of stock at an average price of $28.98. Further credit-facility details will be filed on Form 8-K.
Positive
- Net non-dilutive capital of $500 million raised
- Facility expandable up to $1 billion at mutual discretion
- Share repurchase program increased to $300 million
- Completed repurchases of $38 million at $28.98 average price
- Supports commercial operations including BRIUMVI and pipeline investment
Negative
- New secured debt of $750 million increases secured obligations
- Potential for higher leverage if the facility expands to $1 billion
News Market Reaction – TGTX
On the day this news was published, TGTX gained 1.07%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.5% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $54M to the company's valuation, bringing the market cap to $5.13B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TGTX was down 4.67% with elevated volume, while key biotech peers like MRUS (-7.08%), CRSP (-3.25%) and RNA (-10.47%) were also weaker, suggesting broader biotech pressure, but momentum scanners did not flag a coordinated sector move.
Previous Buybacks Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Sep 03 | Share repurchase update | Positive | +6.7% | Completion of $100M buyback and authorization of new $100M program. |
The only prior buyback announcement showed a positive price reaction that aligned with the constructive nature of the news.
Historically, TG Therapeutics’ capital return announcements have coincided with constructive share price reactions. On Sep 03, 2025, the company completed a $100M repurchase program and authorized a new $100M program, after buying back about 3.5M shares at an average of $28.55. That buyback news saw a 6.66% gain over 24 hours. Today’s expansion of the repurchase authorization and addition of non‑dilutive debt capital fits this ongoing capital deployment theme.
Historical Comparison
Previous buyback news on Sep 03, 2025 led to a 6.66% gain. Today’s larger program expansion and added non‑dilutive credit continue that capital return pattern for TGTX.
Capital return has progressed from completing a $100M buyback and authorizing a new $100M program in 2025 to expanding the current authorization to $300M, supported by additional non‑dilutive debt capacity.
Regulatory & Risk Context
TG Therapeutics has an effective S-3ASR shelf filed on 2025-08-08, allowing issuance of various securities over time. As of the latest data, usage_count is 0, indicating no takedowns under this shelf have been recorded in the context provided.
Market Pulse Summary
This announcement combines a new five-year $750M senior secured credit facility, yielding $500M in net non‑dilutive capital, with an expansion of the share repurchase authorization to $300M. Together, these moves increase financial flexibility for buybacks and strategic initiatives while retiring a prior $250M facility. Historically, TG Therapeutics’ buyback news has coincided with constructive reactions, but investors should track leverage levels, capital allocation pace, and future disclosures on Form 8‑K.
Key Terms
senior secured credit facility financial
non-dilutive capital financial
Form 8-K regulatory
AI-generated analysis. Not financial advice.
Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (“TG” or “the Company”), (NASDAQ: TGTX), today announced that it has entered into a new five-year,
In connection with the new facility, the Company’s Board of Directors authorized an increase to its share repurchase program from
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “We are pleased to announce this expanded credit facility with funds managed by Blue Owl, which significantly enhances our financial position with increased scale and improved terms compared to our prior facility. This financing builds on our cash flow positive business and provides substantial non-dilutive capital to support opportunistic share repurchases and business development, while continuing to invest in the growth of BRIUMVI and advancement of our pipeline.” Weiss continued, “The expansion of our share repurchase program underscores our confidence in our business and our commitment to delivering long-term shareholder value. We appreciate Blue Owl’s continued relationship and support.”
“TG Therapeutics continues to demonstrate strong commercial execution with BRIUMVI and a disciplined approach to growth,” said Sandip Agarwala, Managing Director and Head of Life Sciences at Blue Owl. “We are pleased to deepen our relationship with TG through this expanded facility and support the Company as it continues to advance its strategic initiatives.”
Additional details regarding the credit facility will be filed with the Securities and Exchange Commission on Form 8-K.
ABOUT BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IV
BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses.
BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in several countries outside of the U.S. for the treatment of adult patients with RMS with active disease defined by clinical or imaging features.
A list of authorized specialty distributors can be found at www.briumvi.com.
IMPORTANT SAFETY INFORMATION
Contraindications: BRIUMVI is contraindicated in patients with:
- Active Hepatitis B Virus infection
- A history of life-threatening infusion reaction to BRIUMVI
WARNINGS AND PRECAUTIONS
Infusion Reactions: BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was
Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.
Infections: Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was
Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI.
Hepatitis B Virus (HBV) Reactivation: HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HB surface antigen (HBsAg) and anti-HB tests. For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment.
Progressive Multifocal Leukoencephalopathy (PML): PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. JCV infection resulting in PML has been observed in patients treated with anti-CD20 antibodies, including BRIUMVI, and other MS therapies.
If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.
MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis.
If PML is confirmed, treatment with BRIUMVI should be discontinued.
Vaccinations: Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines, at least 4 weeks and, whenever possible, at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion.
Vaccination of Infants Born to Mothers Treated with BRIUMVI During Pregnancy: In infants of mothers exposed to BRIUMVI during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted.
Fetal Risk: Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose.
Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in
Liver Injury: Clinically significant liver injury, without findings of viral hepatitis, has been reported in the postmarketing setting in patients treated with anti-CD20 B-cell depleting therapies approved for the treatment of MS, including BRIUMVI. Signs of liver injury, including markedly elevated serum hepatic enzymes with elevated total bilirubin, have occurred from weeks to months after administration.
Patients treated with BRIUMVI found to have an alanine aminotransaminase (ALT) or aspartate aminotransferase (AST) greater than 3x the upper limit of normal (ULN) with serum total bilirubin greater than 2x ULN are potentially at risk for severe drug-induced liver injury.
Obtain liver function tests prior to initiating treatment with BRIUMVI, and monitor for signs and symptoms of any hepatic injury during treatment. Measure serum aminotransferases, alkaline phosphatase, and bilirubin levels promptly in patients who report symptoms that may indicate liver injury, including new or worsening fatigue, anorexia, nausea, vomiting, right upper abdominal discomfort, dark urine, or jaundice. If liver injury is present and an alternative etiology is not identified, discontinue BRIUMVI.
Most Common Adverse Reactions: The most common adverse reactions in RMS trials (incidence of at least
Physicians, pharmacists, or other healthcare professionals with questions about BRIUMVI should visit www.briumvi.com.
ABOUT BRIUMVI PATIENT SUPPORT in the U.S.
BRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey in a way that works best for them. More information about the BRIUMVI Patient Support program can be accessed at www.briumvipatientsupport.com.
ABOUT MULTIPLE SCLEROSIS
Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS) and includes people with relapsing-remitting multiple sclerosis (RRMS) and people with secondary progressive multiple sclerosis (SPMS) who continue to experience relapses. RRMS is the most common form of multiple sclerosis (MS) and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. It is estimated that nearly 1 million people are living with MS in the United States and approximately
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
Cautionary Statement
This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the below.
Such forward-looking statements include, but are not limited to, statements regarding the expected benefits of the new credit facility, including the Company’s enhanced financial position and flexibility; the potential availability of additional capital under the facility; the Company’s ability to utilize the proceeds to support the commercial growth of BRIUMVI, advance its pipeline, and execute on capital allocation strategies, including share repurchases; and the Company’s expectations regarding its future financial and operational performance.
Additional factors that could cause our actual results to differ materially include the following: risks related to the Company’s ability to realize the anticipated benefits of the credit facility; risks related to the Company’s ability to access additional capital under the facility; risks related to the Company’s capital allocation strategies, including the timing and amount of any share repurchases; the commercial success of BRIUMVI; the Company’s ability to expand and successfully execute its commercial strategy; the Company’s reliance on third parties for manufacturing, supply, and distribution; the risk that data from clinical trials or post-marketing experience may impact the safety or efficacy profile of BRIUMVI; the Company’s ability to obtain and maintain regulatory approvals; and general economic, market, and business conditions.
Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
| CONTACT: | |
| Investor Relations Email:ir@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 4 Media Relations Email:media@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 6 |
1. MS Prevalence. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/About-the-Society/MS-Prevalence. Accessed October 26, 2020. 2. Multiple Sclerosis International Federation, 2013 via Data monitor p. 236.
FAQ
What did TG Therapeutics (TGTX) announce on March 19, 2026 about new financing?
How much can TG Therapeutics (TGTX) borrow under the expanded credit facility?
What change did TG Therapeutics (TGTX) make to its share repurchase program on March 19, 2026?
How much stock has TG Therapeutics (TGTX) repurchased to date and at what price?
Does the new Blue Owl facility dilute TG Therapeutics (TGTX) shareholders?
Will TG Therapeutics (TGTX) file more details about the credit facility with regulators?
